No relationship between total kindey volume class or genotype and 24h blood pressure control in adult ADPKD patients [PDF]
, 2018 Allamani, Mandelina +4 more
core +2 more sources
Le tolvaptan pour le traitement de la polykystose rénale autosomique dominante – état actuel des connaissances [PDF]
, 2014 Laura Rotar +2 more
openalex +1 more source
The effect of tolvaptan on renal progression and systemic inflammation in ADPKD
Scientific ReportsInflammation plays a crucial role in the progression of autosomal dominant polycystic kidney disease (ADPKD). While tolvaptan is primarily known for its vasopressin V2 receptor antagonism, its potential anti-inflammatory effects remain under ...
Ahmet Ziya Şahin, Orhan Özdemir
doaj +1 more source
Response by Imamura et al. regarding the article “Update of acute and long-term tolvaptan therapy” [PDF]
, 2019 Teruhiko Imamura, Koichiro Kinugawa
openalex +1 more source
Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation
, 2021 Shuko Iwata +6 more
openalex +1 more source
Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR Registry. [PDF]
Can J Kidney Health DisMcFarlane P +4 more
europepmc +1 more source
Severe symptomatic acute hyponatremia in traumatic brain injury responded very rapidly to a single 15 mg dose of oral tolvaptan; a Mayo Clinic Health System hospital experience – need for caution with tolvaptan in younger patients with preserved renal function [PDF]
, 2016 Macaulay Onuigbo, Nneoma Agbasi
openalex +1 more source
P2459The prognostic implication of the diuretic and natriuretic responses to the combined administration of loop diuretics and tolvaptan in patients with acute decompensated heart failure [PDF]
, 2017 Taiki Sakaguchi +4 more
openalex +1 more source